GSA Capital Partners LLP Lowers Stock Holdings in Rockwell Medical, Inc. (NASDAQ:RMTI)

GSA Capital Partners LLP lessened its holdings in shares of Rockwell Medical, Inc. (NASDAQ:RMTI) by 51.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 88,590 shares of the company’s stock after selling 92,766 shares during the quarter. GSA Capital Partners LLP’s holdings in Rockwell Medical were worth $352,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in RMTI. Concurrent Investment Advisors LLC acquired a new stake in shares of Rockwell Medical in the third quarter worth approximately $40,000. Beacon Financial Advisory LLC purchased a new position in Rockwell Medical during the third quarter worth approximately $98,000. Renaissance Technologies LLC boosted its holdings in shares of Rockwell Medical by 877.1% in the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after purchasing an additional 92,189 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Rockwell Medical by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after buying an additional 43,302 shares during the period. Finally, Armistice Capital LLC increased its holdings in shares of Rockwell Medical by 22.5% during the 2nd quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after buying an additional 592,000 shares during the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Rodman & Renshaw began coverage on Rockwell Medical in a report on Thursday, November 14th. They issued a “buy” rating and a $5.00 target price on the stock. RODMAN&RENSHAW raised Rockwell Medical to a “strong-buy” rating in a research note on Thursday, November 14th. StockNews.com downgraded shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Rockwell Medical in a research report on Wednesday, September 11th.

Rockwell Medical Stock Up 2.3 %

Shares of NASDAQ RMTI opened at $2.25 on Friday. The stock has a fifty day moving average price of $3.56 and a 200 day moving average price of $2.63. The company has a market cap of $72.72 million, a P/E ratio of -44.00 and a beta of 1.50. Rockwell Medical, Inc. has a 12-month low of $1.16 and a 12-month high of $5.15. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33.

Rockwell Medical Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.